Dupilumab is effective in children (6-11 years) with moderate-to-severe asthma and high eosinophils at baseline
Jackson D, Hamelmann E, Roberts G, Bacharier L, Altincatal A, Gall R, Ledanois O, Jacob-Nara JA, Amr R, Rowe PJ, Deniz Y (2023)
In: Abstracts from the European Academy of Allergy and Clinical Immunology Hybrid Congress, 9-11 June, 2023. Allergy , 78(S112). Hoboken: Wiley: 185.
Kurzbeitrag Konferenz / Poster
| Veröffentlicht | Englisch
Download
Es wurden keine Dateien hochgeladen. Nur Publikationsnachweis!
Autor*in
Jackson, D.;
Hamelmann, EckardUniBi;
Roberts, G.;
Bacharier, L.;
Altincatal, A.;
Gall, R.;
Ledanois, O.;
Jacob-Nara, J. A.;
Amr, R.;
Rowe, P. J.;
Deniz, Y.
Erscheinungsjahr
2023
Titel des Konferenzbandes
Abstracts from the European Academy of Allergy and Clinical Immunology Hybrid Congress, 9-11 June, 2023
Serien- oder Zeitschriftentitel
Allergy
Band
78
Ausgabe
S112
Seite(n)
185
ISSN
0105-4538
eISSN
1398-9995
Page URI
https://pub.uni-bielefeld.de/record/2988213
Zitieren
Jackson D, Hamelmann E, Roberts G, et al. Dupilumab is effective in children (6-11 years) with moderate-to-severe asthma and high eosinophils at baseline. In: Abstracts from the European Academy of Allergy and Clinical Immunology Hybrid Congress, 9-11 June, 2023. Allergy . Vol 78. Hoboken: Wiley; 2023: 185.
Jackson, D., Hamelmann, E., Roberts, G., Bacharier, L., Altincatal, A., Gall, R., Ledanois, O., et al. (2023). Dupilumab is effective in children (6-11 years) with moderate-to-severe asthma and high eosinophils at baseline. Abstracts from the European Academy of Allergy and Clinical Immunology Hybrid Congress, 9-11 June, 2023, Allergy , 78, 185. Hoboken: Wiley.
Jackson, D., Hamelmann, Eckard, Roberts, G., Bacharier, L., Altincatal, A., Gall, R., Ledanois, O., et al. 2023. “Dupilumab is effective in children (6-11 years) with moderate-to-severe asthma and high eosinophils at baseline”. In Abstracts from the European Academy of Allergy and Clinical Immunology Hybrid Congress, 9-11 June, 2023, 78:185. Allergy . Hoboken: Wiley.
Jackson, D., Hamelmann, E., Roberts, G., Bacharier, L., Altincatal, A., Gall, R., Ledanois, O., Jacob-Nara, J. A., Amr, R., Rowe, P. J., et al. (2023). “Dupilumab is effective in children (6-11 years) with moderate-to-severe asthma and high eosinophils at baseline” in Abstracts from the European Academy of Allergy and Clinical Immunology Hybrid Congress, 9-11 June, 2023 Allergy , vol. 78, (Hoboken: Wiley), 185.
Jackson, D., et al., 2023. Dupilumab is effective in children (6-11 years) with moderate-to-severe asthma and high eosinophils at baseline. In Abstracts from the European Academy of Allergy and Clinical Immunology Hybrid Congress, 9-11 June, 2023. Allergy . no.78 Hoboken: Wiley, pp. 185.
D. Jackson, et al., “Dupilumab is effective in children (6-11 years) with moderate-to-severe asthma and high eosinophils at baseline”, Abstracts from the European Academy of Allergy and Clinical Immunology Hybrid Congress, 9-11 June, 2023, Allergy , vol. 78, Hoboken: Wiley, 2023, pp.185.
Jackson, D., Hamelmann, E., Roberts, G., Bacharier, L., Altincatal, A., Gall, R., Ledanois, O., Jacob-Nara, J.A., Amr, R., Rowe, P.J., Deniz, Y.: Dupilumab is effective in children (6-11 years) with moderate-to-severe asthma and high eosinophils at baseline. Abstracts from the European Academy of Allergy and Clinical Immunology Hybrid Congress, 9-11 June, 2023. Allergy . 78, p. 185. Wiley, Hoboken (2023).
Jackson, D., Hamelmann, Eckard, Roberts, G., Bacharier, L., Altincatal, A., Gall, R., Ledanois, O., Jacob-Nara, J. A., Amr, R., Rowe, P. J., and Deniz, Y. “Dupilumab is effective in children (6-11 years) with moderate-to-severe asthma and high eosinophils at baseline”. Abstracts from the European Academy of Allergy and Clinical Immunology Hybrid Congress, 9-11 June, 2023. Hoboken: Wiley, 2023.Vol. 78. Allergy . 185.
Export
Markieren/ Markierung löschen
Markierte Publikationen
Web of Science
Dieser Datensatz im Web of Science®Suchen in
Google Scholar